United States · FDA National Drug Code directory
Ondansetron
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 43063-857_3ed995a4-00a5-c1d0-e063-6394a90a0298
- Product NDC
- 43063-857
- Form
- TABLET, ORALLY DISINTEGRATING
- Composition / generic term
- Ondansetron
- Labeler
- PD-Rx Pharmaceuticals, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20100412
- Source listing expiry
- 20261231
Source-listed ingredients
- ONDANSETRON — 4 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 2 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (43063-857-02) · 43063-857-02
- 4 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (43063-857-04) · 43063-857-04
- 5 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (43063-857-05) · 43063-857-05
- 6 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (43063-857-06) · 43063-857-06
- 8 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (43063-857-08) · 43063-857-08
- 10 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (43063-857-10) · 43063-857-10
- 20 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (43063-857-20) · 43063-857-20
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →